The active substance is Sofosbuvir and Daclatasvir, which is an inhibitor of the NS5A protein required for the synthesis of HCV.
The main purpose of the drug is antiviral therapy. It is active in the fight against viral hepatitis C (genotypes 1, 2, 3, 4).
The essence of the impact is to block the development of HCV and its spread in the body of the carrier.
HCV exists in different forms known as genotypes.
Genotype 1 is the most common type of HCV genotype and is also the most difficult to treat using other treatments.
Mechanism of Action:
DCV is an HCV NS5A replication complex inhibitor.
This NS5A viral protein has enzymatic activity that is essential for HCV RNA replication and assembly.
In replication it appears to play a role in the formation of a membranous web along with viral protein NS4B, and this web provides a platform for replication.
The NS5A protein is composed of 3 domains;
Domains I and II are essential for HCV replication while the domain III seems to help the vision assembly.
The NS5A inhibitors have high antiviral potency but lower barrier to resistance development.
DCV acts as an NS5A inhibitor by binding within the first 100 amino acids of the amino terminus (i.e. domain 1) of the protein.
DCV results rapidly in serum HCV RNA drop by 2 logs within the first 6 h of administration, followed by a slower phase of decline, suggesting that it blocks vision assembly and release as well as viral RNA synthesis.
Dosage and administration
Sovihep D is given as a 60 mg oral dose once per day with or without food.
Sovihep D should be administered at 60 mg/day or at 30 mg/day when a reduced dose is warranted.
Finally, dosage modification is not required in patients with liver failure Child-Pugh (CP) B or C, in the elderly or in patients with renal or hepatic impairment.
•Nausea and Vomiting
•Severe skin rash and hives
•Shortness of breath
•Chest pain or discomfort
Warning and Contradictions:
Sovihep D 60 Tablet may interact with many other medicines and may cause severe adverse effects. Hence, it is advised that you inform the doctor about all your current medicines including any herbs and supplements before beginning treatment with this medicine.
The most commonly reported AEs were (≥5%): headache (14%), fatigue (14%), nausea (8%), and diarrhea (5%)
|Sofosbuvir and Daclatasvir|
There are no comments yet